File(s) under permanent embargo
Role of dopamine D3 and serotonin 5-HT1A receptors in l-DOPA-induced dyskinesias and effects of sarizotan in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease
journal contribution
posted on 2011-01-01, 00:00 authored by M Gerlach, G Bartoszyk, P Riederer, Olivia DeanOlivia Dean, M van den BuuseSarizotan, a 5-HT1A agonist with additional affinity for D3 and D4 receptors, has been demonstrated to have anti-dyskinetic effects. The mechanism by which these effects occur is not clear. Using unilateral 6-hydroxydopamine-lesioned rats that received chronic intraperitoneal (ip) administration of L-3,4-dihydroxyphenylalanine (L-DOPA) we investigated the involvement of D3 and 5-HT1A receptors in the effects of sarizotan on contraversive circling and abnormal involuntary movements (AIMs). Before sensitization by chronic L-DOPA treatment (12.5 with 3.25 mg/kg benserazide ip, twice daily for 21 days), no effect of the selective D3 agonist, PD128907 (1 or 3 mg/kg ip), or the selectiveD3 antagonist,GR103691 (0.5 or 1.5 mg/kg ip), was observed. Treatment with sarizotan (1 or 5 mg/kg ip) dosedependently inhibited the L-DOPA-induced contraversive turning and AIMs. In co-treatment with the 5-HT1A antagonist, WAY100635 (1 mg/kg ip), sarizotan failed to affect this behaviour, confirming the prominent 5-HT1A receptor-mediated mechanism of action. In the presence of PD128907 (3 mg/kg ip), the effects of sarizotan on contraversive turning, locomotive dyskinesia and axial dystonia, but not on orolingual and forelimb dyskinesia, were blocked. On its own, PD128907 had no effect on the behavioural effects of L-DOPA except that it tended to reduce orolingual and forelimb dyskinesia. GR103691 had no effect on its own or in combination with sarizotan. These data identify an involvement of D3 receptors in the action of sarizotan on some, but not all L-DOPA-induced motor side effects. This selective involvement is in contrast to the more general involvement of 5-HT1A receptors in the anti-dyskinetic effects of sarizotan.
History
Journal
Journal of neural transmissionVolume
118Issue
12Pagination
1733 - 1742Publisher
SpringerLocation
Amsterdam, The NetherlandsPublisher DOI
ISSN
1435-1463Publication classification
C1.1 Refereed article in a scholarly journalCopyright notice
2011, Springer-VerlagUsage metrics
Categories
No categories selectedKeywords
L-DOPA-induced dyskinesiaabnormal involuntary movementssarizotanParkinson therapydopamine D3 receptorsserotonin 5-HT1A receptorsScience & TechnologyLife Sciences & BiomedicineClinical NeurologyNeurosciencesNeurosciences & NeurologyDopamine D-3 receptorsLEVODOPA-INDUCED DYSKINESIADORSAL RAPHE NUCLEUSMOTOR COMPLICATIONSBEHAVIORAL SENSITIZATIONMESSENGER-RNAAGONISTSTIMULATIONANTAGONISTSEXPRESSION
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC